IOL Chemicals and Pharmaceuticals Reports Q3 & 9M FY25: Revenue Stable, EBITDA and PAT Margins Show Varied Trends
The PAT Margin for Q3 FY25 was 3.90%, with a 30 basis point increase quarter-over-quarter but a 49 basis point decline year-over-year.
IOL Chemicals and Pharmaceuticals Reports Rs 527.37 Crore Revenue in Q3 FY25
13th February, 2025, Delhi: IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for quarter and nine months year ended 31st December, 2024.
IOL Chemicals and Pharmaceuticals has reported its standalone financial highlights for Q3 and 9M FY25. The company's Total Income for Q3 FY25 was Rs 527.37 crore, reflecting a slight decrease of 0.90% compared to the previous quarter and a marginal decline of 0.26% year-over-year. The EBITDA for Q3 FY25 stood at Rs 50.94 crore, showing a 6.15% increase quarter-over-quarter but a 3.63% decrease year-over-year. The EBITDA Margin improved to 9.66%, with a 64 basis point increase quarter-over-quarter but a 34 basis point decline year-over-year. Profit After Tax (PAT) for Q3 FY25 was Rs 20.55 crore, marking a 7.31% increase quarter-over-quarter but an 11.54% decrease year-over-year. The PAT Margin for Q3 FY25 was 3.90%, with a 30 basis point increase quarter-over-quarter but a 49 basis point decline year-over-year.
For the nine months ended December 31, 2024 (9M FY25), the Total Income was Rs 1569.31 crore, representing a 4.97% decrease year-over-year. The EBITDA for 9M FY25 was Rs 157.11 crore, a 22.98% decrease year-over-year, with an EBITDA Margin of 10.01%, showing a decline of 234 basis points. The PAT for 9M FY25 was Rs 69.38 crore, reflecting a 35.30% decrease year-over-year, and the PAT Margin was 4.42%, with a decrease of 207 basis points.
Join PSU Connect on WhatsApp now for quick updates! Whatsapp Channel
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment.
Confident of our resilient performance, the Board has declared an interim dividend of Rs. 4/- (40%) per share of face value of Rs 10 each for financial year 2024-25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our long-term vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position. ”
Read Also : HLL and SECL signs MoU; will improve hygiene management in 22 Government SchoolsAbout IOL Chemicals and Pharmaceuticals Limited (IOLCP)
Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.
The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.
The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.
The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.
IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.
Read Also : RBI to soon issue Rs 100 and Rs 200 banknotes with new Governor’s signature